

Western Region Drugs Task Force Company Limited By Guarantee

Annual Report and Financial Statements

for the financial year ended 31 December 2019

Western Region Drugs Task Force Company Limited By Guarantee
CONTENTS

	Page
Directors and Other Information	3
Directors' Report	4 - 5
Directors' Responsibilities Statement	6
Independent Auditor's Report	7 - 8
Appendix to the Independent Auditor's Report	9
Income and Expenditure Account	10
Balance Sheet	11
Reconciliation of Members' Funds	12
Cash Flow Statement	13
Notes to the Financial Statements	14 - 20
Supplementary Information on Trading Statement	22 - 23

**Western Region Drugs Task Force Company Limited By Guarantee
DIRECTORS AND OTHER INFORMATION**

Directors

Nuala Ford (Resigned 12 March 2019)
Richard O'Donovan
Joseph O'Neill (Appointed 12 March 2019)

Company Secretary

Joseph O'Neill (Appointed 12 March 2019)
Nuala Ford (Resigned 12 March 2019)

Company Number

460340

Registered Office

Unit 6 Galway Technology Park
Parkmore
Galway

Business Address

Unit 6 Galway Technology Park
Parkmore
Galway

Auditors

DFS & Co Audit Services Limited
Chartered Accountants & Statutory Audit Firm
2nd Floor
Innovation House
Ballybrit Business Park
Ballybrit
Galway

Bankers

Bank of Ireland
Mervue Industrial Estate
Galway

Solicitors

Sheehan & Co Solicitors
Augustine Court
St Augustine Street
Galway

Western Region Drugs Task Force Company Limited By Guarantee

DIRECTORS' REPORT

for the financial year ended 31 December 2019

The directors present their report and the audited financial statements for the financial year ended 31 December 2019.

Principal Activity and Review of the Business

The principal activity of the charity is to develop and implement an integrated community, voluntary and statutory strategy to combat substance abuse in Galway, Mayo & Roscommon.

The Company is limited by guarantee not having a share capital.

There has been no significant change in these activities during the financial year ended 31 December 2019.

Principal Risks & Uncertainties

The principal risks and uncertainties facing the charity are its reliance for funding on state agencies and on donations which may decline causing a cut-back in service levels. The board are confident that they can adapt the company's expenditure to its income and they do not foresee any significant cut in funding for the current year.

Financial Results

The (deficit)/surplus for the financial year after providing for depreciation amounted to €(21,161) (2018 - €33,431).

At the end of the financial year, the company has assets of €83,583 (2018 - €113,680) and liabilities of €54,624 (2018 - €63,560). The net assets of the company have decreased by €(21,161).

Reserves Strategy

The Board has set a reserves policy which requires reserves to be maintained at a level which would cover Western Region Drugs Taskforce's operating costs for a period of two consecutive months. This would enable current operating activities to continue in the short term should there be a significant drop in funding. At least one months operating costs should be maintained in a cash or cash equivalent reserve.

Directors and Secretary

The directors who served throughout the financial year, except as noted, were as follows:

Nuala Ford (Resigned 12 March 2019)
Richard O'Donovan
Joseph O'Neill (Appointed 12 March 2019)

The secretaries who served during the financial year were;

Joseph O'Neill (Appointed 12 March 2019)
Nuala Ford (Resigned 12 March 2019)

In accordance with the Constitution, the directors retire by rotation and, being eligible, offer themselves for re-election.

Future Developments

The company will continue to seek funding from government bodies to carry out its charitable activities.

Post Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

Political Contributions

The company did not make any disclosable political donations in the current financial year.

Auditors

The auditors, DFS & Co Audit Services Limited, (Chartered Accountants & Statutory Audit Firm) have indicated their willingness to continue in office in accordance with the provisions of section 383(2) of the Companies Act 2014.

Statement on Relevant Audit Information

In accordance with section 330 of the Companies Act 2014, so far as each of the persons who are directors at the time this report is approved are aware, there is no relevant audit information of which the statutory auditors are unaware. The directors have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and they have established that the statutory auditors are aware of that information.


Western Region Drugs Task Force Company Limited By Guarantee
DIRECTORS' REPORT

for the financial year ended 31 December 2019

Accounting Records

To ensure that adequate accounting records are kept in accordance with sections 281 to 285 of the Companies Act 2014, the directors have employed appropriately qualified accounting personnel and have maintained appropriate computerised accounting systems. The accounting records are located at the company's office at Unit 6 Galway Technology Park, Parkmore, Galway.

Signed on behalf of the board



Joseph O'Neill
Director



Richard O'Donovan
Director

24 March 2020

Western Region Drugs Task Force Company Limited By Guarantee

DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 31 December 2019

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under the law the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the surplus or deficit of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:


- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and surplus or deficit of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014 and enable the financial statements to be readily and properly audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed on behalf of the board



Joseph O'Neill
Director



Richard O'Donovan
Director

24 March 2020

INDEPENDENT AUDITOR'S REPORT

to the Members of Western Region Drugs Task Force Company Limited By Guarantee

Report on the audit of the financial statements

Opinion

We have audited the financial statements of Western Region Drugs Task Force Company Limited By Guarantee ('the company') for the financial year ended 31 December 2019 which comprise the Income and Expenditure Account, the Balance Sheet, the Reconciliation of Members' Funds, the Cash Flow Statement and the related notes to the financial statements, including a summary of significant accounting policies set out in note 2. The financial reporting framework that has been applied in their preparation is Irish Law and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31 December 2019 and of its deficit for the financial year then ended;
- have been properly prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard; and
- have been properly prepared in accordance with the requirements of the Companies Act 2014.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with ethical requirements that are relevant to our audit of financial statements in Ireland, including the Ethical Standard for Auditors (Ireland) issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and the Provisions Available for Audits of Small Entities, in the circumstances set out in note 5 to the financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Material uncertainty related to going concern

There is a material uncertainty related to events or conditions that may cast significant doubt on the entity's ability to continue as a going concern and, therefore, that it may be unable to realise its assets and discharge its liabilities in the normal course of business.

In forming our opinion on the financial statements, which is not modified, we have considered the adequacy of the disclosure made in note 3 to the financial statements concerning the company's ability to continue as a going concern. While the company incurred a deficit of €21,161 during the year ended 31st December 2019 and, at that date, it had creditors of €54,622, the company had Members Funds of €28,959. These conditions, along with the other matters explained in note 3 to the financial statements, indicate the existence of a material uncertainty which may cast significant doubt about the company's ability to continue as a going concern. The financial statements do not include the adjustments that would result if the company was unable to continue as a going concern.

Other Information

The directors are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our Auditor's Report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2014

Based solely on the work undertaken in the course of the audit, we report that:

- in our opinion, the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- in our opinion, the Directors' Report has been prepared in accordance with the Companies Act 2014.

We have obtained all the information and explanations which we consider necessary for the purposes of our audit.

In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited. The financial statements are in agreement with the accounting records.

INDEPENDENT AUDITOR'S REPORT

to the Members of Western Region Drugs Task Force Company Limited By Guarantee

Matters on which we are required to report by exception

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified any material misstatements in the Directors' Report. The Companies Act 2014 requires us to report to you if, in our opinion, the disclosures of directors' remuneration and transactions required by sections 305 to 312 of the Act are not made. We have nothing to report in this regard.

Respective responsibilities

Responsibilities of directors for the financial statements

As explained more fully in the Directors' Responsibilities Statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the company or to cease operation, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is contained in the appendix to this report, located at page 9, which is to be read as an integral part of our report.

The purpose of our audit work and to whom we owe our responsibilities

Our report is made solely to the company's members, as a body, in accordance with section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an Auditor's Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume any responsibility to anyone other than the company and the company's members, as a body, for our audit work, for this report, or for the opinions we have formed.



Maria Doonan

for and on behalf of

DFS & CO AUDIT SERVICES LIMITED

Chartered Accountants & Statutory Audit Firm

2nd Floor

Innovation House

Ballybrit Business Park

Ballybrit

Galway

24 March 2020

Western Region Drugs Task Force Company Limited By Guarantee APPENDIX TO THE INDEPENDENT AUDITOR'S REPORT

Further information regarding the scope of our responsibilities as auditor

As part of an audit in accordance with ISAs (Ireland), we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditor's Report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditor's Report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Western Region Drugs Task Force Company Limited By Guarantee INCOME AND EXPENDITURE ACCOUNT


for the financial year ended 31 December 2019

	Notes	2019 €	2018 €
Income		265,191	274,445
Expenditure		<u>(286,352)</u>	<u>(241,014)</u>
(Deficit)/surplus before tax		(21,161)	33,431
Tax on (deficit)/surplus		-	-
(Deficit)/surplus for the financial year		<u>(21,161)</u>	<u>33,431</u>
Total comprehensive income		<u><u>(21,161)</u></u>	<u><u>33,431</u></u>

Approved by the board on 24 March 2020 and signed on its behalf by:



Joseph O'Neill
Director



Richard O'Donovan
Director

Western Region Drugs Task Force Company Limited By Guarantee

BALANCE SHEET

as at 31 December 2019


	Notes	2019 €	2018 €
Fixed Assets			
Tangible assets	8	9,765	6,448
Current Assets			
Debtors	9	23,434	23,434
Cash and cash equivalents		50,384	83,798
		73,818	107,232
Creditors: Amounts falling due within one year	10	(54,624)	(63,560)
Net Current Assets		19,194	43,672
Total Assets less Current Liabilities		28,959	50,120
Reserves			
Income and expenditure account		28,959	50,120
Members' Funds		28,959	50,120

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

Approved by the board on 24 March 2020 and signed on its behalf by:



 Joseph O'Neill
 Director



 Richard O'Donovan
 Director

Western Region Drugs Task Force Company Limited By Guarantee

RECONCILIATION OF MEMBERS' FUNDS

as at 31 December 2019

	Retained surplus	Total
	€	€
At 1 January 2018	16,689	16,689
Surplus for the financial year	33,431	33,431
At 31 December 2018	50,120	50,120
Deficit for the financial year	(21,161)	(21,161)
At 31 December 2019	28,959	28,959

Western Region Drugs Task Force Company Limited By Guarantee

CASH FLOW STATEMENT

for the financial year ended 31 December 2019

	Notes	2019 €	2018 €
Cash flows from operating activities			
(Deficit)/surplus for the financial year		(21,161)	33,431
Adjustments for:			
Depreciation		2,384	1,671
		<u>(18,777)</u>	<u>35,102</u>
Movements in working capital:			
Movement in debtors		-	(23,432)
Movement in creditors		(8,936)	14,585
		<u>(27,713)</u>	<u>26,255</u>
Cash flows from investing activities			
Payments to acquire tangible fixed assets		(5,701)	(1,962)
		<u>(33,414)</u>	<u>24,293</u>
Net (decrease)/increase in cash and cash equivalents		(33,414)	24,293
Cash and cash equivalents at beginning of financial year		83,798	59,505
Cash and cash equivalents at end of financial year	18	<u>50,384</u>	<u>83,798</u>

Western Region Drugs Task Force Company Limited By Guarantee

NOTES TO THE FINANCIAL STATEMENTS

for the financial year ended 31 December 2019

1. GENERAL INFORMATION

Western Region Drugs Task Force Company Limited By Guarantee is a company limited by guarantee incorporated in the Republic of Ireland. The registered office of the company is Unit 6 Galway Technology Park, Parkmore, Galway. The nature of the company's operations and its principal activities are set out in the Directors' Report. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the year ended 31 December 2019 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Income

Grants

Grant Income from government agencies and other sundry sources are included in the Financial Statements on the basis of the amounts received and receivable.

Income

Income consisting of donations and other funds generated by voluntary activity are included in the Financial Statements when received. Income from these sources have been included in the Financial Statements only when realised or when the ultimate cash realisation of which can be assessed with reasonable certainty.

Fund Accounting

The following funds are operated by the charity:

- Restricted Funds

Restricted funds represent grants, donations and sponsorship received which can only be used for particular purposes specified by the donors or sponsorship programmes binding on the directors. Such purposes are within the overall aims of the charity.

- Unrestricted Funds

Unrestricted Funds represent amounts which are expendable at the discretion of the directors in furtherance of the objectives of the charity and which have not been designated for other purposes. Such funds may be held in order to finance working capital or capital expenditure.

Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible fixed assets, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment	- 12.5% Straight Line
----------------------------------	-----------------------

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Western Region Drugs Task Force Company Limited By Guarantee

NOTES TO THE FINANCIAL STATEMENTS

continued

for the financial year ended 31 December 2019

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable income for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Income and Expenditure Account.

3. DEPARTURE FROM COMPANIES ACT 2014 PRESENTATION

The directors have elected to present an Income and Expenditure Account instead of a Profit and Loss Account in these financial statements as this company is a not-for-profit entity.

4. GOING CONCERN

The Financial Statements have been prepared on the going concern basis of accounts preparation, the validity of which depends upon future funding being available on a continuous basis from government agencies. The Directors are taking all necessary steps to ensure the continuation of support from the company's funding agencies. The Directors are confident that the company will receive funding for the foreseeable future which will allow the company to continue to operate. This uncertainty could result in the company being unable to realise its assets and discharge its liabilities in the normal course of business.

5. PROVISIONS AVAILABLE FOR AUDITS OF SMALL ENTITIES

In common with many other businesses of our size and nature, we use our auditors to prepare and submit tax returns to the Revenue and to assist with the preparation of the financial statements.

6. OPERATING (DEFICIT)/SURPLUS	2019	2018
	€	€
Operating (deficit)/surplus is stated after charging:		
Depreciation of tangible fixed assets	2,384	1,671

7. EMPLOYEES

There were no company employees during the year.

Western Region Drugs Task Force Company Limited By Guarantee
NOTES TO THE FINANCIAL STATEMENTS

continued

for the financial year ended 31 December 2019

8. TANGIBLE FIXED ASSETS

	Fixtures, fittings and equipment €	Total €
Cost		
At 1 January 2019	13,372	13,372
Additions	5,701	5,701
	<u>19,073</u>	<u>19,073</u>
Depreciation		
At 1 January 2019	6,924	6,924
Charge for the financial year	2,384	2,384
	<u>9,308</u>	<u>9,308</u>
Net book value		
At 31 December 2019	<u>9,765</u>	<u>9,765</u>
At 31 December 2018	<u><u>6,448</u></u>	<u><u>6,448</u></u>
9. DEBTORS	2019	2018
	€	€
Taxation	2	2
Prepayments	23,432	23,432
	<u>23,434</u>	<u>23,434</u>
10. CREDITORS	2019	2018
Amounts falling due within one year	€	€
Accruals	4,305	3,690
Deferred Income	50,319	59,870
	<u>54,624</u>	<u>63,560</u>

Repayment Terms

Accruals do not attract interest and their terms vary depending on contracts in place. Other Creditors do not attract interest and are due for immediate payment. Deferred Income is repayable in the event that funding is not used for the purpose for which it was intended.

Western Region Drugs Task Force Company Limited By Guarantee
NOTES TO THE FINANCIAL STATEMENTS

continued

for the financial year ended 31 December 2019

11. State Funding

Agency	TUSLA- Child and Family Agency
Type of Funding	QCBI Funding
Grant Programme	Planet Youth
Purpose of the Grant	To implement the Plant Youth Model for Primary Prevention in Roscommon
Total Grant	€19,474
Grant taken to I&E	€19,474
Received in the financial year	€19,474
Amounts deferred or due at financial year end	Nil
Expenditure	€19,474
Term	12 Months (January 2019 - December 2019)
Date Received	21/09/2019
Capital Grant	Nil
Restriction on Use	Restricted to implementing the Plant Youth model for primary prevention of substance misuse
Tax Clearance	Yes
Agency	TUSLA- Child and Family Agency
Type of Funding	CYPSC Galway & Roscommon
Grant Programme	Planet Youth
Purpose of the Grant	To implement the Plant Youth Model for Primary Prevention
Total Grant	€3,750
Grant taken into I&E	€3,750
Received in the financial year	€3,750
Amounts deferred or due at financial year end	Nil
Expenditure	€3,750
Term	12 Months (January 2019 - December 2019)
Date Received	13/09/2019
Capital Grant	Nil
Restricted on Use	Restricted to implementing the Plant Youth model for primary prevention of substance misuse
Tax Clearance	Yes

Western Region Drugs Task Force Company Limited By Guarantee
NOTES TO THE FINANCIAL STATEMENTS

continued

for the financial year ended 31 December 2019

Agency	TUSLA- Child and Family Agency
Type of Funding	CYPSC Galway
Grant Programme	Planet Youth
Purpose of the Grant	To implement the Planet Youth Model for Primary Prevention
Total Grant	€8,000
Grant taken into I&E	€8,000
Received in the financial year	€8,000
Amounts deferred or due at financial year end	Nil
Expenditure	€8,000
Term	12 Months (January 2019 - December 2019)
Date Received	09/10/2019
Capital Grant	Nil
Restricted on Use	Restricted to implementing the Planet Youth model for primary prevention of substance misuse
Tax Clearance	Yes
Agency	TUSLA- Child and Family Agency
Type of Funding	CYPSC Galway
Grant Programme	Planet Youth
Purpose of the Grant	To implement the Planet Youth Model for Primary Prevention
Total Grant	€4,000
Grant taken into I&E	€4,000
Received in the financial year	€4,000
Amounts deferred or due at financial year end	Nil
Expenditure	€4,000
Term	12 Months (January 2019 - December 2019)
Date Received	13/12/2019
Capital Grant	Nil
Restricted on Use	Restricted to implementing the Planet Youth model for primary prevention of substance misuse
Tax Clearance	Yes

Western Region Drugs Task Force Company Limited By Guarantee
NOTES TO THE FINANCIAL STATEMENTS

continued

for the financial year ended 31 December 2019

Agency	TUSLA- Child and Family Agency
Type of Funding	QCBI Funding 2018 - C/O to 2019
Grant Programme	Planet Youth Roscommon
Purpose of the Grant	To implement the Plant Youth Model for Primary Prevention in Roscommon
Total Grant	€13,646 of €19,473 grant received in December 2018
Grant taken into I&E	€13,646
Received in the financial year	Nil (€13,646 received & deferred in 2018)
Amounts deferred or due at financial year end	Nil
Expenditure	€13,646
Term	12 Months (December 2018 - November 2019)
Date Received	07/12/2018
Capital Grant	Nil
Restriction on Use	Restricted to implementing the Plant Youth model for primary prevention of substance misuse
Tax Clearance	Yes

12. STATUS

The liability of the members is limited.

Every member of the company undertakes to contribute to the assets of the company in the event of its being wound up while they are members, or within one year thereafter, for the payment of the debts and liabilities of the company contracted before they ceased to be members, and of the costs, charges and expenses of winding up, and for the adjustment of the rights of the contributors among themselves, such amount as may be required, not exceeding € 1.

13. CAPITAL COMMITMENTS

The company had no material capital commitments at the financial year-ended 31 December 2019.

14. CONTINGENT LIABILITIES

The company is funded by the provision of grant aid from the Health Service Executive (HSE) & the National Lottery. These grants may become repayable in the whole or in part if the company does not adhere to terms and conditions set down in funding agreements.

15. DIRECTORS' REMUNERATION

No remuneration was paid to any members of the Board of directors.

16. RELATED PARTY TRANSACTIONS

There were no related party transactions with the directors during the period.

17. POST-BALANCE SHEET EVENTS

There have been no significant events affecting the company since the year end.

Western Region Drugs Task Force Company Limited By Guarantee
NOTES TO THE FINANCIAL STATEMENTS

continued

for the financial year ended 31 December 2019

18. CASH AND CASH EQUIVALENTS	2019	2018
	€	€
Cash and bank balances	35,290	47,345
Cash equivalents	15,094	36,453
	<u>50,384</u>	<u>83,798</u>

19. RESERVES

Reserves represent the accumulated surplus earned by the company since incorporation.

20. APPROVAL OF FINANCIAL STATEMENTS

The financial statements were approved and authorised for issue by the board of directors on 24 March 2020.

WESTERN REGION DRUGS TASK FORCE COMPANY LIMITED BY GUARANTEE

SUPPLEMENTARY INFORMATION

RELATING TO THE FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2019

NOT COVERED BY THE REPORT OF THE AUDITORS

THE FOLLOWING PAGES DO NOT FORM PART OF THE AUDITED FINANCIAL STATEMENTS

Western Region Drugs Task Force Company Limited By Guarantee
SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS

TRADING STATEMENT

for the financial year ended 31 December 2019

Schedule	2019 €	2018 €
Income		
HSE Funding	105,841	96,841
Hse Funding - Family Support Mayo	46,326	46,326
HSE National Lottery Grants	8,000	-
HSE Funding - Bursaries Income	18,844	-
Tulsa Funding - Planet Youth	15,750	17,417
Funding Other Sources	150	-
National Family Support Network	-	200
National Addiction Training Program - Prime for Life	-	17,786
Department of Social Protection	-	3,603
HSE Healthy Cities Funding	17,061	-
South West Mayo Development Company	300	7,984
Galway Roscommon Education Training Board	4,800	13,917
Galway Roscommon Education Training Board - Planet Youth	-	4,000
Galway City & County Council - Planet Youth	11,250	8,250
Mayo County Council	-	3,483
Tulsa QCBI Planet Youth	33,119	39,905
Health & Wellbeing - Planet Youth	3,750	14,733
	<u>265,191</u>	<u>274,445</u>
Gross surplus Percentage	<u>100.0%</u>	<u>100.0%</u>
Overhead expenses	1 (286,352)	(241,014)
Net (deficit)/surplus	<u><u>(21,161)</u></u>	<u><u>33,431</u></u>

Western Region Drugs Task Force Company Limited By Guarantee
SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS

SCHEDULE 1 : OVERHEAD EXPENSES

for the financial year ended 31 December 2019

	2019 €	2018 €
Administration Expenses		
WRDATF Training	16,254	15,062
Rent & Services payable	26,155	17,286
Light and heat	4,617	4,003
Cleaning & Waste	2,475	1,961
Repairs and maintenance	3,939	2,958
Printing, postage and stationery	15,661	12,290
Printing, postage & stationery - Planet Youth	1,567	1,066
General Advertising	1,499	111
Telephone	4,918	4,878
Computer costs	3,900	3,278
App Development	-	1,427
Digital Technology	12,782	-
Training Ancillary Costs	5,527	15,373
Consultancy fees	8,007	-
Accountancy	1,722	1,230
Bank charges	139	223
General expenses	-	150
Rehab Bursary Applications	18,845	-
Conference Expenses	-	1,285
Prime for Life	-	17,888
Ballinrobe Family Resource Centre	46,326	47,564
Plant Youth	83,924	80,839
Awareness Week	6,109	8,011
Family Support Fund	16,834	-
Auditor's remuneration	2,768	2,460
Depreciation of tangible fixed assets	2,384	1,671
	<u>286,352</u>	<u>241,014</u>